

CLAIM AMENDMENTS

1-47. (canceled)

48. (currently amended): A method to identify an agent that decreases ~~the expression status of~~ 101P3A11 protein activity, ~~which method comprises~~ comprising:

~~identifying cells that~~ providing a first sample of cells and a second sample of cells, wherein the cells of each sample express 101P3A11 (SEQ ID NO:2866);

~~contacting [[a]] the first sample of said cells with a candidate compound under conditions wherein the expression status of the 101P3A11 protein is observable; and~~

~~observing said contacted cells for at least one property characteristic of said expression status of said 101P3A11 protein activity in the first sample with the candidate compound;~~

~~observing [[a]] 101P3A11 protein activity in the second sample of said cells which have , wherein the second sample has not been contacted with said candidate compound for said at least one property characteristic of the expression status of the 101P3A11 protein;~~

~~comparing the observed property~~ 101P3A11 protein activity in said first and second samples ~~sample;~~

~~whereby a diminution in the property exhibited by~~ 101P3A11 protein activity in said first sample as compared to said second sample identifies said compound as an agent that decreases ~~the expression status of~~ 101P3A11 protein activity.

49. (canceled)

50. (previously presented): The method of claim 48, wherein said cells have been modified to contain an expression system for said 101P3A11 protein.

51-53. (canceled)

54. (new) The method of claim 48, wherein the candidate compound is an antibody that binds specifically to the 101P3A11 protein.

55. (new) The method of claim 48, wherein the 101P3A11 activity comprises 101P3A11-mediated ERK phosphorylation.

56. (new) The method of claim 48, wherein the 101P3A11 activity comprises 101P3A11-mediated cAMP accumulation.